Payer and Health Technology Assessments

Regulatory approval is only one decision. Payers and HTA bodies also ask whether a therapy improves on existing care, whether the benefit lasts, what the service costs, and whether the health system can deliver it.

In Europe, some assessment is becoming more coordinated through EU Joint Clinical Assessments, but coverage and payment still depend heavily on national systems. A developer may need one clinical evidence package that can be adapted to different country questions.

This page explains what payers and HTA bodies look for: comparative evidence, durability, safety monitoring, cost-effectiveness, budget impact, service capacity, and uncertainty plans.

What payers need to know

Clinical benefit

Comparative evidence

HTA bodies usually ask how a treatment performs against the care patients would otherwise receive. Placebo-controlled trials may support approval, but payers often want standard-of-care or active-comparator evidence. EU Joint Clinical Assessments add shared clinical review, while national systems still make the reimbursement decision.[16]1

Direct comparisons are clearest

Head-to-head evidence is usually easiest for payers to interpret because it shows how the new treatment performs against the care patients would otherwise receive.

Head-to-head trials can show how a new treatment compares with antidepressants, psychotherapy, esketamine, ketamine services, ECT, or other care used in the target population. Outside esketamine, few psychedelic programs have built this kind of payer-facing comparison yet.

When indirect comparisons are used

Indirect treatment comparisons can help when head-to-head trials are unavailable. They compare results across separate studies that share enough common features to support a cautious comparison.

Active-placebo designs can help with blinding, but they can also make payer interpretation harder. If both arms include psychological support, or if the active placebo has its own therapeutic effect, reviewers may still ask how the package compares with ordinary care.

Under the EU Joint Clinical Assessment procedure, indirect comparisons can matter when head-to-head trials are unavailable. National HTA bodies still differ in how much uncertainty they accept, so developers should explain the limits of any indirect comparison rather than treating it as a substitute for direct evidence.

Indirect comparisons can be useful, but they are fragile. Patient populations may differ between trials, outcomes may be measured differently, and statistical assumptions can drive the result. Developers should document assumptions clearly and run sensitivity analyses (van Beekhuizen et al., 2024). NICE also warns that small evidence networks are prone to bias and may need population-adjusted methods when trials are imbalanced (NICE, 2023).

Researchers should use established methods for indirect comparisons and explain the limits clearly. Network meta-analyses and matching-adjusted indirect comparisons can help, but they depend on comparable populations, outcomes, and reporting. EU Joint Clinical Assessment may cover clinical effectiveness, while national bodies can still ask for local economic evidence.

EU joint assessment, national decisions

Joint Clinical Assessment can reduce duplicated HTA work across the EU, but Member States still make local access decisions. Developers therefore need evidence that works at both levels. For psychedelics, that means addressing blinding, expectancy effects, psychological support, comparators, and payer-relevant outcomes before national submissions begin.

Subgroups can shape eligibility

Subgroup analyses show whether a treatment works differently across patient groups inside an approved indication. Payers use them when added benefit is unclear, the eligible population is large, or the budget impact is high. In those cases, reimbursement may be limited to the groups most likely to benefit.

Why payers ask for subgroups

HTA bodies and payers use subgroup analyses to refine value assessments. NICE (2013; 2023) asks for subgroup-specific clinical and cost-effectiveness estimates when biological or clinical reasons suggest different treatment effects. These estimates help target reimbursement to patients most likely to benefit. Countries then apply the evidence differently: some restrict reimbursement to specific subgroups, while Germany evaluates clinical benefit across all indicated patients and uses subgroup results in pricing discussions.[17]2

Plan subgroup analysis early

Good subgroup analyses need careful planning and explicit methods. Groups should be defined before the analysis begins, with clear reasoning based on biological or clinical factors (EC, 2024). While exploratory analyses can generate new ideas, investigators must interpret them carefully to avoid overestimating effects. Statistical tests for interaction can help prove that subgroup differences are real, especially when results are consistent across multiple studies.

Key challenges include maintaining statistical accuracy with smaller patient numbers and managing multiple comparisons. Small subgroups can lead to unreliable results or bias. Testing many subgroups or outcomes requires statistical adjustments to maintain reliable conclusions, using established statistical methods or more advanced modelling approaches.

How subgroups affect access

Subgroup analysis matters for psychedelic therapies because response may vary by indication, prior treatment, comorbidity, demographics, genetics, and psychological factors. Comparing treatment-resistant depression with less resistant depression, for example, can show where the value case is strongest and where reimbursement should be narrower.

Well-designed subgroup analysis can support fairer access decisions. It helps payers avoid both overbroad coverage and unnecessary exclusion by showing which patients are most likely to benefit and which groups still need more evidence.

Cost-effectiveness

What economic models have to show

Health economic models ask whether a treatment is a good use of limited healthcare funds. They compare costs with health benefits, often through the incremental cost-effectiveness ratio (ICER): the extra cost needed to gain one quality-adjusted life year, or QALY.

For psychedelic therapies, cost-effectiveness and cost-utility analyses need to show both the upfront care cost and the possible downstream savings. The models should test fewer hospital stays, fewer relapses, lower medicine use, and uncertainty about durability. Scenario testing matters because long-term results are still uncertain.

Early economic evidence

European economic modelling for psychedelic therapies is still developing. Early studies provide useful frameworks, but they depend heavily on pricing assumptions, comparator choice, treatment-delivery costs, and the durability of benefit (McCrone et al., 2023; Buiter, 2023). Psilocybin modelling in UK depression has shown possible health gains, while also indicating that cost-effectiveness may require lower therapist or drug costs.

Similar challenges emerge in other European analyses, such as the evaluation of MDMA therapy for PTSD in the Netherlands, where researchers found that while cost-effectiveness ratios could fall within acceptable ranges, this heavily depends on the choice of comparator treatments and key assumptions about therapy delivery and outcomes (Buiter, 2023).[18]3

Target population changes the value case

Target population changes the reimbursement case. First-line depression or PTSD populations are large and often have inexpensive standard options, so a high-touch psychedelic therapy has a harder cost-effectiveness case even if it works clinically.

Later-line and treatment-resistant populations can be easier to justify at launch. Existing care may already be costly or ineffective, unmet need is clearer, and a narrower eligible group reduces early budget pressure.

What goes into the model

1. Models need the full cost of care: medicine, preparation, dosing-session staff time, rooms, monitoring, integration, follow-up, adverse-event management, and any later retreatment. Indirect costs such as time off work or caregiver burden are included only in some country methods.

1. Models also need outcomes that payers can use. That can include symptom response, remission, relapse, quality of life, hospitalization, medication use, and patient-reported outcomes. Analysts then project how those outcomes change over time.

1. Time horizon matters because psychedelic therapies may have high upfront costs and possible longer-term benefits. Models often need 5- to 10-year views, with explicit assumptions about waning benefit, relapse, retreatment, and discounting of future costs and gains.

1. Sensitivity analyses show which assumptions drive the result. For psychedelic therapies, key tests include treatment cost, therapist time, durability, retreatment rate, eligible population, uptake speed, and downstream healthcare use.

Country differences in economic evaluation

EU HTA rules may align clinical assessment, but economic evaluation remains national. Countries use different perspectives, thresholds, and budget rules, so one model usually needs country-specific versions.

• Germany (IQWiG/G-BA): Health economics plays no role in the national benefit assessment but can be useful in access discussions with individual health insurance companies.

• Netherlands (ZiN): uses cost-effectiveness evidence for reimbursement decisions and can include a societal perspective when broader benefits are relevant, such as productivity gains or reduced caregiver burden. Flexible thresholds are linked to disease severity.

• United Kingdom (NICE): usually focuses on direct NHS and personal social services costs, with common cost-effectiveness thresholds around GBP20,000-GBP30,000 per QALY. Supplementary societal analyses may help explain value but rarely drive the base case.

• Czech Republic (SUKL): uses a healthcare-system perspective focused mainly on direct medical costs and resource use, with budget impact and affordability central to the reimbursement decision.

These differences mean the same psychedelic therapy can look more attractive in one market than another, especially where broader value is counted or higher thresholds apply for severe disease.

Upfront cost versus long-term savings

Payers are cautious when a treatment requires large upfront spending. Psychedelic therapies concentrate costs in preparation, supervised dosing, monitoring, and integration, while the hoped-for savings may only appear months or years later.

Economic cases for psychedelic treatments need to show the tradeoff: upfront costs for delivery, facilities, and therapist training versus later savings from fewer hospital stays, lower medication use, or return to work. Flexible payment approaches, including phased coverage or payment by results, may help where the eligible treatment-resistant population is large enough to create budget concern.[19][19][19]4

Indirect costs and broader benefits

Indirect costs describe effects outside direct medical spending: time off work, reduced work capacity, caregiver burden, disability payments, and early death. These can matter for depression, PTSD, addiction, and other conditions where better functioning may change a patient's life beyond the clinic.

Health economists use two main approaches to calculate indirect costs (Mennini & Gitto, 2022):

• Human Capital Method: Estimates lost productivity based on the time individuals cannot work, valuing their absence at average wage rates.

• Friction Cost Method: Focuses on the costs of temporarily replacing an employee who cannot work, accounting for labour market dynamics and adjustments.

For psychedelic therapies, indirect-benefit claims should stay specific. A durable improvement could support return to work or reduced caregiver burden, but payers will want credible measurement rather than broad claims about social value.

How Europe treats indirect costs

European countries differ in how much broader economic value they count. That difference can materially change how a psychedelic therapy is modelled and discussed.

England and the Czech Republic generally focus on direct healthcare costs in the base case. That can make it harder for broader productivity or caregiver benefits to change the main reimbursement conclusion.

The Netherlands, Sweden, and Denmark may be more open to a societal perspective, depending on the file and method. That can make broader benefits more relevant, but the evidence still has to be credible.

Some countries, including France and Belgium, may consider broader impacts in supplementary analyses while keeping the primary assessment narrower. Developers should know which argument belongs in the base case and which belongs in supporting analysis.

Budget impact

Affordability and budget impact

Budget impact analyses (BIAs) assess how new treatments affect healthcare spending, typically over 3-5 years. Unlike cost-effectiveness analyses, BIAs focus on practical affordability within existing budgets. They estimate the financial impact on the pharmaceutical drug budget or, potentially, the combined budget impact across the health system related to overall service delivery.

Budget impact analyses can produce very different answers depending on what they count. A drug-only analysis will look much cheaper than one that includes rooms, monitoring, therapist time, and service setup. When budget impact looks high, payers are more likely to use restrictions, phased access, or price negotiations.

European approaches to budget impact

The European and U.S. healthcare systems differ in how they approach affordability and financial planning.[20]5 In Europe, public healthcare systems often focus on cost containment and equitable access, using centralised negotiations to determine coverage and pricing. BIAs in Europe often emphasise system-level affordability and resource allocation, reflecting broader societal goals.

Most European countries will require budget impact analysis of a new drug's expected national direct drug costs over 3-5 years at a minimum. Some budget analyses stipulate the inclusion of all direct costs to the health system. The Netherlands’ ZiN methodology incorporates societal costs into economic models, extending the scope of BIAs beyond direct healthcare spending.

Budget questions for psychedelic therapies

Psychedelic therapies create budget questions because costs are front-loaded. Instead of a daily medicine cost spread across years, the system may face a concentrated episode of preparation, dosing, monitoring, integration, and follow-up. Key questions include:

• Patient population: How many people qualify in the first three to five years, and how much will eligibility rules limit uptake?

• Comparator and care costs: What does the therapy replace: generic medicines, psychotherapy, esketamine, inpatient care, crisis services, or another pathway?

• Cost Comparisons: How do psychedelics compare to conventional treatments (e.g., SSRIs or CBT) in terms of annual costs and resource use? Will payers consider cost comparisons to non-pharmaceutical therapies, which are often more cost-intensive?

• Cost Offsets: What savings can health systems expect from quicker hospital discharges, reduced hospitalisations, less emergency care, or reduced long-term medication use?

Target population selection and budget impact

When developing psychedelic therapies, companies must choose between broad indications such as depression or PTSD and narrower treatment-resistant groups. Starting with smaller, high-need populations can reduce initial budget impact and improve payer acceptance while evidence builds in specialist clinics. Broader indications may create a larger access opportunity, but they also raise stronger concerns about cost and scalability.

A phased approach, starting with treatment-resistant conditions before expanding to broader populations, often works best. It helps prove value while managing costs, and gives health systems time to build infrastructure and gather real-world evidence before expansion.

Engaging with HTA bodies

HTA bodies judge whether a new treatment offers enough value for its cost. For psychedelic therapies, that means assessing both the drug effect and the care model around it: preparation, dosing support, monitoring, integration, durability, and safety.

This section examines HTA processes in Germany, the United Kingdom, the Netherlands, and the Czech Republic. Each country has distinct requirements. For instance, Germany focuses on proving any added clinical benefit compared to existing treatments, while the UK emphasises cost-effectiveness thresholds. The Netherlands and Czech Republic pay particular attention to affordability and broader societal benefits. Understanding these differences helps developers plan their evidence generation and effectively engage with HTA bodies to support access to psychedelic therapies.

Understanding HTA processes in target countries

Germany (G-BA and IQWiG)

Germany assesses new medicines after approval through AMNOG. G-BA sets the benefit-assessment requirements, while IQWiG reviews the evidence that informs those decisions. For psychedelic therapies, the key question is whether trials show added patient-relevant benefit against the comparator G-BA expects, not only whether regulators approve the medicine.

Initial submission process

The AMNOG process begins immediately after a therapy enters the German market. Within three months of market entry, IQWIG begins assessing the manufacturer's dossier detailing the therapy's clinical and economic evidence to the G-BA. This dossier includes data on efficacy, safety, and patient-relevant outcomes and comparative evidence against the appropriate comparator therapy determined by the G-BA.

This step introduces complexities for psychedelic therapies, as the combined drug-and-therapy model necessitates data not only on the pharmacological intervention but also on the accompanying psychotherapy if it is part of the indication. Developers must demonstrate the synergy between the two components, clearly outlining how this integrated approach provides superior clinical outcomes compared to existing treatments.

Early benefit assessment

Once the dossier is submitted, the G-BA commissions IQWiG to conduct an early benefit assessment (frühe Nutzenbewertung). This assessment evaluates the therapy’s comparative effectiveness, improvements in patient-relevant outcomes such as mortality, morbidity, quality of life, and safety profiles. IQWiG does not conduct health economic evaluations. However, the IQWiG assessment forms the foundation for G-BA’s later pricing negotiations with the manufacturer.

The early benefit assessment focuses heavily on comparative evidence, requiring head-to-head trials wherever possible. When such data are unavailable, developers may need to rely on ITCs, which are scrutinised for methodological rigour and relevance.

Benefit classification and pricing

After IQWiG's evaluation, the G-BA decides whether the therapy adds benefit over standard care. The G-BA grades added benefit as major, considerable, minor, non-quantifiable, none, or lower benefit. Higher grades support stronger price negotiations. Orphan-designated therapies below the relevant annual-cost threshold must receive at least a non-quantifiable added benefit from the G-BA.

For psychedelic therapies, a major or considerable added-benefit rating would strengthen the reimbursement case. Long-term efficacy and durability matter because TRD and PTSD therapies are likely to face close scrutiny on sustained impact and safety. Spravato, for example, received a considerable benefit rating in Germany because of patient-relevant benefits in TRD.

Price negotiations and market access

The G-BA’s decision also sets the stage for price negotiations between the manufacturer and Germany’s statutory health insurance association (GKV-Spitzenverband). During the first 6 months of market entry, manufacturers can set their own prices, but subsequent pricing depends on the G-BA’s benefit classification. The GKV typically negotiates therapies rated with no added benefit at parity with or even below existing treatments. In contrast, those demonstrating major or considerable benefit have the potential to achieve higher prices than the existing standard of care.

Post-marketing requirements

G-BA can require post-marketing evidence to monitor long-term outcomes and safety. For psychedelic therapies, this could mean Phase IV studies, registries, or real-world evidence on durability, side effects, and integration protocols. Developers should expect to document assumptions, data sources, and follow-up methods clearly.

Service-model challenges and system integration

Germany has a clear HTA framework, but combined drug-therapy models create billing problems. GOA and EBM codes may not capture intensive psychological support, long supervised sessions, or integration work, which can limit practical access even after a positive assessment.[21]6 Outpatient providers also face budget constraints and may hesitate to offer high-cost treatments without explicit reimbursement guarantees from insurers.

German adoption depends on practical funding routes, especially in outpatient settings and for therapist time. Esketamine offers some parallels, but psychedelic therapy adds longer clinic visits, preparation, integration, and more complex supervision. Those costs need a payment pathway before access can scale.

Germany's HTA system sets a high bar for evidence quality and directly links drug pricing to it. While this presents a challenge for psychedelic therapies, it also provides opportunities to demonstrate their potential as paradigm-shifting treatments for psychiatric disorders. Developers must strategically plan their evidence-generation activities, considering the ability to deliver clinical trials with head-to-head comparative data, the costs and complexity of doing so, and the implications of not doing this on drug pricing in Germany, which is usually an early launch market.

United Kingdom (NICE and SMC)

In the United Kingdom, the evaluation and reimbursement of new therapies falls under the jurisdiction of the National Institute for Health and Care Excellence (NICE) in England and Wales, and the Scottish Medicines Consortium (SMC) in Scotland. The NICE process focuses on evidence-based recommendations and ensuring cost-effectiveness for treatments introduced into the National Health Service (NHS) (NICE, 2023).

Unlike many European countries, the UK does not follow the European Medicines Agency (EMA) approval pathway, requiring manufacturers to engage directly with the Medicines and Healthcare products Regulatory Agency (MHRA) for market authorisation before proceeding to NICE evaluations.[22]7

NICE health technology assessment routes

Therapies seeking NHS adoption generally follow one of three routes: NICE Health Technology Appraisals (HTA), NHS clinical policy development, or the Clinical Priorities Advisory Group (CPAG) process​.

Among these routes, NICE HTA is the main national pathway for treatments seeking routine NHS funding. It evaluates clinical benefit, cost-effectiveness, and likely service impact, then issues recommendations that shape NHS access. CPAG may be relevant for small, high-need populations, but it covers only a limited number of interventions each year. NHS clinical policy development is more relevant for interventions outside NICE's remit, especially where the central question is how a service should be delivered rather than whether a specific new technology should be reimbursed.

Topic selection and scoping

The NICE process begins with topic selection, usually after a referral from the Department of Health and Social Care or NHS England. During scoping, NICE defines the target population, comparators, outcomes, and other assessment questions. For psychedelic therapies, this step would need to account for therapy integration, supervision, setting, and follow-up, because those factors shape both comparators and cost-effectiveness models.

Technology appraisal framework

Psychedelic therapies are likely to undergo NICE’s Single Technology Appraisal (STA) process, which focuses on assessing one drug for a specific indication. The STA model requires manufacturers to submit detailed dossiers containing clinical trial data, health economic models, and budget impact analyses​ (BIAs).

Given the therapy-drug combination inherent in psychedelic treatments, submissions must address both pharmacological efficacy and the therapy’s delivery framework. NICE evaluates these submissions through independent Evidence Review Groups (ERGs), which appraise the evidence base for clinical and cost-effectiveness​.

Appraisal committees and consultation

NICE convenes an independent Appraisal Committee to review evidence and hear input from stakeholders. The committee bases decisions on clinical trial data, cost-utility analyses (typically using QALYs), and economic models that address uncertainties through sensitivity analyses.

Particular scrutiny of psychedelic therapies is likely to focus on the duration and resource intensity of treatment protocols, including therapist time and infrastructure needs. NICE’s reliance on cost-effectiveness thresholds—commonly £20,000–£30,000 per QALY—creates a hard hurdle for therapies with high upfront costs, reinforcing the importance of modelling long-term cost offsets​. In 2022, NICE introduced a severity modifier, allowing the approval of treatments for some severe diseases with a higher cost-effectiveness threshold.

NICE draft guidance is released as an Appraisal Consultation Document before the Final Appraisal Determination. A positive recommendation creates an NHS adoption obligation within 90 days. A negative appraisal can lead to appeal, further evidence requests, or little meaningful NHS access.

During the HTA process, manufacturers may refine the requested patient population for reimbursement or amend the position in the care pathway to take account of initial NICE recommendations of UK clinical practice and the likelihood of meeting cost-effectiveness thresholds. Additionally, manufacturers may reduce the therapy's net price to increase the certainty of meeting cost-effectiveness criteria and the likelihood of a positive final HTA recommendation.

Managed access and real-world evidence

NICE can use Managed Access Agreements to grant conditional access while requiring further data collection. This approach may be useful for psychedelic therapies if uncertainty remains around durability, real-world effectiveness, service use, or long-term economic value.

The Innovative Medicines Fund (IMF) may provide interim funding for a few therapies while real-world data is collated or longer-term studies are taking place. NICE can later revise recommendations based on this real-world evidence and make a final determination on cost-effectiveness and NHS funding and access.

Regulatory and implementation challenges

Despite the rigorous evaluation framework, psychedelic therapies face additional hurdles due to their controlled substance status. Prescribing requirements, storage conditions, and clinical supervision protocols need to be aligned. These factors necessitate collaboration between NICE, the Medicines Value and Access Team (MVAT), and possibly the Home Office, to streamline regulatory and health system implementation.

The Netherlands (ZiN)

In the Netherlands, Zorginstituut Nederland (ZiN) manages HTAs for new therapies, including psychedelics. ZiN determines whether to recommend a treatment for inclusion in the statutory health insurance (SHI) package (basispakket) based on its clinical effectiveness, cost-effectiveness, necessity, and feasibility.

Given the distinct combination of drugs and psychotherapy in psychedelic treatments, the assessment framework must address both pharmacological efficacy and the broader therapeutic context, making this evaluation more complex than for conventional medications.

Regulatory pathway and submission requirements

After EMA approval, manufacturers seeking Dutch reimbursement submit a dossier to ZiN (ZiN, 2024). The dossier needs clinical data, cost-utility analysis, and information on societal impact. ZiN assesses it through package-management criteria (pakketbeheercriteria), including effectiveness, cost-effectiveness, necessity, and feasibility.

These criteria include effectiveness, cost-effectiveness, necessity, and feasibility. Clinical outcomes, such as improvements in symptoms or quality of life, supported by evidence from randomised controlled trials (RCTs) or real-world data, demonstrate effectiveness. ZiN evaluates cost-effectiveness using incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs) to determine whether the therapy provides sufficient value for its cost compared to existing treatments. Necessity focuses on whether the therapy addresses a clear unmet medical need. At the same time, feasibility examines whether providers can integrate it practically into the Dutch healthcare system, considering infrastructure requirements and professional training.

The "Lock" (Sluis) Process for High-Cost Therapies

The Netherlands employs an additional review process known as the "lock" (sluis) for therapies with high costs or large projected budget impacts. This process applies to treatments exceeding €50,000 per patient and €10 million annually in projected costs. It involves more stringent assessments of cost-effectiveness and affordability, often requiring additional data collection post-launch.

Psychedelic treatments are unlikely to fit the ordinary Dutch lock pathway cleanly. If a therapy enters the lock, it faces further negotiations and may receive only conditional approval while long-term evidence is collected.

Decision-making and reimbursement

ZiN compiles its recommendations into an advisory report for the Minister of Health, Welfare, and Sport, who ultimately decides whether to include the therapy in the basic health insurance package. The advisory report evaluates whether the treatment meets the four key criteria and may propose conditions for reimbursement, such as limiting use to specific patient populations or requiring providers to participate in registries to track long-term outcomes.

For example, psychedelic therapies could be approved only for patients who have not responded to multiple lines of treatment, reflecting a cautious approach similar to that taken with esketamine for TRD. Price negotiations may also follow, particularly for high-cost therapies, with managed entry agreements and risk-sharing arrangements used to balance payer concerns with patient access​.

If the Minister approves a therapy, it is listed in the Geneesmiddelenvergoedingssysteem (GVS), the Dutch medicine reimbursement system. One route covers medicines without added restrictions; another allows reimbursement with eligibility rules or other conditions. Early psychedelic therapies are more likely to need conditions while clinicians gain experience and researchers collect additional data.

Cost-utility modelling and indirect benefits

A key feature of the Dutch HTA process is its emphasis on cost-utility modelling and societal perspectives. The process includes indirect costs and benefits, such as productivity gains and reduced caregiver burden, in its economic evaluations. The Dutch broader perspective aligns well with the potential long-term benefits of psychedelic therapies, particularly for conditions like PTSD and TRD.

ZiN uses willingness-to-pay thresholds that rise with disease severity and burden. Developers therefore need strong evidence on how severe the target condition is and how much burden it creates. This is often weaker than teams expect: across therapeutic areas, many HTA submissions struggle to demonstrate disease severity well enough to support higher thresholds.

Ongoing monitoring and real-world evidence

Conditional approvals often require post-marketing surveillance and ongoing data collection to address uncertainties. Psychedelic therapies may be subject to additional scrutiny, with requirements to participate in registries or conduct Phase IV trials to verify long-term safety and effectiveness. ZiN can also re-evaluate therapies as new evidence emerges, adjusting reimbursement conditions or withdrawing coverage if expectations are unmet.

Challenges for psychedelic therapies

While the combination of drug administration and therapeutic support in psychedelic treatments presents a novel evaluation scenario, existing healthcare codes and care pathways may provide useful frameworks for assessing the psychotherapeutic components. The challenge lies primarily in adapting these established structures to this emerging treatment paradigm.

For new treatments like psychedelics, ZiN maintains high standards for evidence quality and cost-effectiveness modelling, including careful evaluation of treatment comparisons. While this presents certain hurdles, the Dutch system's mechanisms for managed entry agreements and conditional approvals provide a structured but adaptable pathway for integrating novel therapies into standard care, particularly when direct comparative evidence may be limited.

Czech Republic (SÚKL)

In the Czech Republic, new therapies undergo a structured HTA process managed by the State Institute for Drug Control (SÚKL). This evaluation focuses on clinical effectiveness, cost-effectiveness, and budgetary impact to determine eligibility for inclusion in the public health insurance system. Most new drugs, particularly innovative therapies like psychedelics, secure centralised marketing authorisation through the EMA. Once the EMA grants approval, it applies across EU Member States, including the Czech Republic, streamlining the initial regulatory phase.

A national authorisation route through SÚKL remains an option for less complex therapies, although developers rarely pursue this route for innovative treatments. Instead, developers of psychedelic therapies are more likely to rely on EMA approval and direct their efforts toward addressing the Czech Republic’s economic and logistical requirements for reimbursement. This approach reduces duplication of scientific evaluations and positions EMA approval as a baseline for local pricing and coverage discussions.

Dossier submission and HTA evaluation

Following EMA authorisation, manufacturers submit a detailed dossier to SÚKL to request registration and inclusion in the public health insurance system. The dossier comprises clinical data, economic models, and budget impact analyses tailored to the Czech healthcare landscape. Clinical evidence is typically derived from the EMA’s centralised assessment, minimising the need for re-evaluation. However, pharmacoeconomic models must be customised to demonstrate cost-effectiveness in the Czech context.

SÚKL applies strict requirements for proving therapeutic value and cost-efficiency. Submissions must quantify health gains using incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs) metrics. The agency also requires budget impact analyses to estimate the financial consequences of adopting the therapy, accounting for patient numbers, pricing, and resource use. For psychedelic therapies, this means addressing both drug costs and the logistical requirements of therapist-led sessions and specialised treatment environments.

Pricing and reimbursement decisions

A key component of the national pricing and reimbursement process is determining the maximum ex-factory price, known as the “maximální cena výrobce.” SÚKL relies on international reference pricing, comparing costs across EU Member States. Typically, prices from a basket of selected countries cannot exceed the average of the three lowest country prices. This external price benchmarking approach helps control drug pricing and drug costs, but would not manage non-drug costs associated with supervised administration and psychotherapy requirements.

Reimbursement decisions classify drugs into different categories, ranging from full coverage to partial reimbursement with restrictions. Expensive or novel therapies are often subject to conditional reimbursement agreements, particularly if long-term effectiveness data are still emerging. For psychedelics, these agreements may limit coverage to specific subgroups, such as patients with TRD, or require prescribing within specialised clinics to ensure safety and protocol adherence.

Budget impact analysis and economic modeling

Budget impact analyses (BIAs) address the broader financial implications of adding new therapies to the public health system. Payers scrutinise whether the treatment’s costs are sustainable under existing budgets. If projected costs exceed predefined thresholds, manufacturers may be required to negotiate risk-sharing agreements, such as budget caps or outcomes-based pricing models, to control expenditures.

Economic models for psychedelic therapies must include the medicine and the care around it: preparation, monitoring, dosing sessions, and integration. To justify higher upfront costs, developers need evidence of later savings, such as fewer hospitalisations, reduced medication use, or lower service demand. Conditional reimbursement can include periodic reassessment to test whether those savings appear in practice.

Implementation and real-world monitoring

Once a therapy is approved for reimbursement, SÚKL lists it in the Czech "List of Reimbursed Medicinal Products," which details pricing, reimbursement levels, and prescribing conditions. Physicians and pharmacists must follow these prescribing conditions when prescribing and dispensing, particularly for therapies requiring controlled environments or specialised training, such as psychedelics. SÚKL monitors treatment outcomes through pharmacovigilance programs, ensuring continued safety and efficacy.

Given the novel nature of psychedelic therapies, SÚKL is likely to recommend conditional reimbursement. This designation allows temporary coverage while mandating additional data collection through patient registries or post-marketing studies. This evidence supports future reassessments, enabling SÚKL to refine reimbursement terms or expand coverage based on updated findings.

Therapies that fail to meet expectations during follow-up evaluations may face restrictions or removal from reimbursement lists. Conversely, positive real-world outcomes can justify broader use, reinforcing the importance of strong initial data submissions and ongoing evidence generation for psychedelic therapies.

Special considerations for psychedelic therapies

Psychedelic therapies create specific HTA challenges because they combine a medicine with structured psychological support. SÚKL would need to assess the pharmacological component and the psychotherapy elements, which complicates economic modelling. Evaluators would also consider therapist training, treatment facilities, and regulatory compliance, all of which differ from standard pharmaceutical interventions.

Psychedelics also face additional scrutiny under the Czech Republic’s narcotics regulations. Controlled substances require licensing and oversight, adding administrative and legal hurdles to their implementation. Societal attitudes and ethical debates may further influence policymakers, highlighting the need for stakeholder engagement and transparent communication about therapeutic benefits and safeguards.

Preparing HTA submissions

Preparing submissions for HTA bodies requires combining evidence about a treatment's effectiveness and value. This combination is complex for psychedelic therapies because submissions must cover both the drug effects and therapy components, showing how they work together to help patients.

Submissions need clinical trial results, comparisons with existing treatments, economic analysis, and budget impact estimates. The comparison with current care is especially important. Economic models should include therapist time, facilities, monitoring, and follow-up, while testing whether longer-term savings or quality-of-life gains offset those costs.

Since psychedelic therapies are new, HTA bodies will question their long-term effects. Developers can address these concerns by testing different scenarios in their economic models, suggesting ways to collect more data as clinicians roll out treatments, and being transparent about what researchers know and do not know.

Submissions often benefit from input from doctors, patients, and advocacy groups during the HTA process. Doctors can explain why new treatments are needed, while patients can describe how conditions or specific treatments affect their lives. These perspectives will help demonstrate the broader benefits of psychedelic therapies and increase the chances of approval.

The most effective approach in preparing for HTA submission is to use early advice or early engagement meetings wherever possible. HTA bodies offer these opportunities, ranging from informal discussions with broad-ranging advice to extremely structured processes where reviewers answer specific questions or validate evidence-generation plans. Developers should understand that some advice is binding, while other advice is only guidance, requiring developers to clearly understand the process before initiating engagement.

Innovative reimbursement models

Innovative reimbursement models represent a dynamic interface between manufacturers and payers, offering mechanisms to manage uncertainties while enabling access to promising therapies. These models may be particularly relevant for psychedelic treatments, where long-term outcomes and durability of effect remain areas of active investigation. Given the novelty and complexity of these therapies, which combine pharmacological and psychotherapeutic elements, standard pricing and reimbursement approaches may prove limiting, and they could benefit from considering the following approaches.

Outcomes-based agreements / performance agreements

One potential approach is performance-linked reimbursement, where payers tie payments to predefined patient outcomes. For psychedelic therapies, these outcomes could include sustained remission rates, reductions in hospitalisations, or improvements in quality-of-life metrics. Such agreements reduce financial risk for payers by ensuring that payments reflect real-world effectiveness rather than relying solely on clinical trial data. However, developers must address challenges in defining appropriate metrics and establishing mechanisms for long-term data collection early in the negotiation process.

Managed entry agreements

Conditional coverage arrangements, also known as managed entry agreements, allow therapies to enter the market while additional evidence is collected. These models are particularly useful when early clinical data shows promise, but gaps remain regarding long-term efficacy or safety. For psychedelics, this approach could help balance the urgency of treating patients with severe conditions against the need for ongoing evidence generation.

Value-based pricing

Another option for psychedelic therapies is flexible pricing strategies based on therapeutic benefits. Value-based pricing aligns costs with demonstrated clinical and economic value, reflecting the therapy’s impact on patient outcomes and healthcare resource use. For psychedelics, this might involve accounting for indirect cost savings, such as productivity gains and reduced caregiver burden, to justify higher upfront costs. However, implementing value-based pricing requires credible health-economic modelling and transparent agreements on how value is measured over time, and some payer groups have considered and then abandoned this approach in the past.

A particular challenge for psychedelic therapies in value-based models is the cost structure of delivery. Unlike traditional pharmaceuticals, where manufacturers minimise production costs and maintain pricing flexibility within their margin, psychedelic treatments include substantial fixed costs for therapist time and monitoring that must be paid immediately, regardless of long-term outcomes. The immediate payment requirement for substantial fixed costs creates practical constraints on implementing value-based pricing that are not present with conventional drug-only interventions.

These models are discussed in more detail in the Potential Reimbursement and Access Pathways section. Their value is that they pair access with evidence generation: patients can receive care under defined conditions while payers collect data on outcomes, costs, safety, and durability.

2026 update: HTA and payer expectations are becoming more explicit

The practical question is no longer whether HTA bodies can assess psychedelic interventions. It is whether programmes can produce evidence that is strong enough for coverage decisions.

Methods updates and implementation guidance indicate stronger expectations for transparent comparators, resource use assumptions and scenario testing for non-drug components.

Implementation takeaways

• Use transparent assumptions for therapist time, supervision and treatment setting intensity.

• Publish sensitivity scenarios that reflect realistic service constraints, not ideal trial conditions.

• Prepare evidence narratives for both national and regional payer contexts.

Sources

• NICE health technology evaluations manual (PMG36) (National Institute for Health and Care Excellence (NICE), 2026-03-31)

• Regulation (EU) 2021/2282 on health technology assessment (European Commission, 2021-12-15)

• PsyPal Guidance Paper 2026 (Uppsala summary) (Uppsala University, 2026-03-30)